natgillin/translations-raw huggingface dataset:
For the comparators typical resistance was detected with TDF/FTC/EFV (SINGLE; six with NNRTI associated resistance and one with major NRTI resistance) and with 2 NRTIs + raltegravir (SPRING2; four with major NRTI resistance and one with raltegravir resistance), while no de novo resistance was detected in patients treated with 2 NRTIs + DRV/RTV (FLAMINGO).
Za usporedne je lijekove tipična rezistencija primijećena kod primjene kombinacije TDF/FTC/EFV (SINGLE; šest s rezistencijom na NNRTI i jedan sa značajnom rezistencijom na NRTI) te kod kombinacije 2 NRTI-ja + raltegravir (SPRING-2; četiri sa značajnom rezistencijom na NRTI i jedan s rezistencijom na raltegravir), dok de novo rezistencija nije otkrivena u bolesnika liječenih kombinacijom 2 NRTI-ja + DRV/RTV (FLAMINGO).
If you could get pregnant while receiving Triumeq, you need to use a reliable method of barrier contraception (for example, a condom) with other methods of contraception including oral (pill) or other hormonal contraceptives (for example, implants, injection), to prevent pregnancy.
Ako biste mogli zatrudnjeti dok primate lijek Triumeq, morate primjenjivati pouzdanu metodu barijerne kontracepcije (na primjer kondom) uz druge metode kontracepcije, uključujući oralne
Both the time to viral suppression and change from baseline analyses were pre-specified and adjusted for multiplicity.
I analiza vremena do virusne progresije i analiza promjene od početne vrijednosti bile su unaprijed određene i prilagođene za multiplicitet.
Sulfamethoxazole: AUC ↔
sulfametoksazol: AUC ↔
In previously untreated patients receiving dolutegravir + 2 NRTIs in Phase IIb and Phase III, no development of resistance to the integrase class, or to the NRTI class was seen (n=876, follow-up of 48-96 weeks).
U prethodno neliječenih bolesnika koji su u ispitivanjima faze IIb i faze III primali dolutegravir + 2 nukleozidna inhibitora reverzne transkriptaze (NRTI) nije primijećen razvoj rezistencije na skupinu inhibitora integraze niti na skupinu NRTI-ja (n=876, praćenje u trajanju od 48-96 tjedana).
If you have stopped taking Triumeq for any reason - especially because you think you are having side effects, or because you have other illness:
Ako ste iz bilo kojeg razloga prestali uzimati Triumeq - osobito ako ste to učinili zato što mislite da imate nuspojave ili zato što imate druge bolesti:
The analyses included two randomized, international, double-blind, activecontrolled trials, SINGLE (ING114467) and SPRING-2 (ING113086), the international, open-label, active-controlled trial FLAMINGO (ING114915), and the randomized, open-label, active-controlled, multicentre, non-inferiority study ARIA (ING117172).
Analize su obuhvatile dva randomizirana, međunarodna, dvostruko slijepa aktivno kontrolirana ispitivanja - SINGLE (ING114467) i SPRING-2 (ING113086), međunarodno, otvoreno, aktivno kontrolirano ispitivanje FLAMINGO (ING114915) te randomizirano, otvoreno, aktivno kontrolirano, multicentrično ispitivanje neinferiornosti ARIA
- The other ingredients are mannitol (E421), microcrystalline cellulose, povidone (K29/32), sodium starch glycolate, magnesium stearate, poly(vinyl) alcohol - partially hydrolysed, titanium dioxide, macrogol/PEG, talc, iron oxide black and iron oxide red).
Drugi sastojci su manitol (E421), mikrokristalična celuloza, povidon (K29/32), natrijev škroboglikolat, magnezijev stearat, djelomično hidrolizirani poli(vinilni alkohol), titanijev dioksid, makrogol/PEG, talk, crni željezov oksid i crveni željezov oksid).
The pharmacokinetics of abacavir have been studied in patients with mild hepatic impairment (Child-Pugh score 5-6) receiving a single 600 mg dose.
Farmakokinetika abakavira ispitivana je u bolesnika s blagim oštećenjem jetrene funkcije (Child-Pugh rezultat: 5-6) koji su primili jednokratnu dozu od 600 mg.
HIV-1 isolates (CRF01_AE, n=12; CRF02_AG, n=12; and Subtype C or CRF_AC, n=13) from 37 untreated patients in Africa and Asia were susceptible to abacavir (IC50 fold changes < 2.5), and lamivudine (IC50 fold changes < 3.0), except for two CRF02_AG isolates with fold changes of 2.9 and 3.4 for abacavir.
Izolati HIV-1 (CRF01_AE, n=12; CRF02_AG, n=12; i podvrsta C ili CRF_AC, n=13) prikupljeni u 37 neliječenih bolesnika u Africi i Aziji bili su osjetljivi na abakavir (promjena IC50 < 2,5 puta) i lamivudin (promjena IC50 < 3,0 puta), osim dvaju izolata CRF02_AG kod kojih se vrijednost za abakavir promijenila 2,9 i 3,4 puta.
If ABC hypersensitivity cannot be ruled out on clinical grounds, ABC should be permanently discontinued and should not be restarted, regardless of the results of HLA-B*5701 screening.
Ako se klinički ne može isključiti preosjetljivost na abakavir, primjena abakavira mora se trajno obustaviti i ne smije se ponovno započeti, neovisno o rezultatima probira na HLA-B*5701.
Overall the available data from observational cohorts and from randomised trials show some inconsistency so can neither confirm nor refute a causal relationship between abacavir treatment and the risk of myocardial infarction.
Sveukupno su dostupni podaci iz opservacijskih kohorti i randomiziranih ispitivanja pokazali određenu razinu nedosljednosti, pa se uzročna povezanost između liječenja abakavirom i rizika od infarkta miokarda ne može ni potvrditi ni opovrgnuti.
If Triumeq is used in patients co-infected with hepatitis B an additional antiviral is, therefore, generally needed.
Dakle, ako Triumeq uzimaju bolesnici s istodobnom infekcijom hepatitisom B, u načelu je potreban dodatan antivirotik.
Before you are prescribed Triumeq your doctor will arrange a test to find out whether you carry a particular type of gene called HLA-B*5701.
Prije nego što Vam propiše Triumeq, liječnik će napraviti pretragu kojom će utvrditi jeste li nositelj jedne određene vrste gena koji se zove HLA-B*5701.
Based on this data, dolutegravir is not expected to affect the pharmacokinetics of medicinal products that are substrates of major enzymes or transporters (see section 4.5).
Na temelju ovih podataka, ne očekuje se da će dolutegravir utjecati na farmakokinetiku lijekova koji su supstrati glavnih enzima ili prijenosnika (vidjeti dio 4.5).
For patients receiving lamivudine 300 mg once daily, the terminal intracellular half-life of lamivudine-TP was 16 to 19 hours.
U bolesnika koji su primali lamivudin u dozi od 300 mg jedanput na dan, terminalni unutarstanični poluvijek lamivudintrifosfata iznosio je 16 do 19 sati.
At 96 weeks, virologic suppression in the dolutegravir group (80%) was superior to the DRV/r group (68%), (adjusted treatment difference [DTG-(DRV+RTV)]: 12.4%; 95% CI: [4.7, 20.2]).
U 96. tjednu, virološka supresija u dolutegravir skupini (80%) bila je superiorna u odnosu na DRV/r skupinu (68 %) (prilagođena razlika između liječenja [DTG-(DRV+RTV)]: 12,4%; 95% CI: [4,7;
If you have stopped taking Triumeq for any reason - especially because you think you are having side effects, or because you have another illness:
Ako ste iz bilo kojeg razloga prestali uzimati Triumeq - osobito ako ste to učinili zato što mislite da imate nuspojave ili zato što imate neku drugu bolest:
Following multiple oral doses of abacavir 300 mg twice a day there is no significant accumulation of abacavir.
Nakon višekratnih peroralnih doza abakavira od 300 mg dvaput na dan nije bilo značajne kumulacije abakavira.
Nervous system disorders: Very common:
Poremećaji živčanog sustava: vrlo često:
Triumeq is recommended to be administered 2 hours before or 6 hours after taking supplements or multivitamins containing calcium, iron or magnesium (see section 4.5).
Preporučuje se primijeniti Triumeq 2 sata prije ili 6 sati nakon primjene nadomjestaka ili multivitaminskih pripravaka koji sadrže kalcij, željezo ili magnezij (vidjeti dio 4.5).
Current ART N=278 n (%)
Trenutna antiretrovirusna terapija N=278 n (%)
The systemic exposure at the no effect level in mice and rats was equivalent to 3 and 7 times the human systemic exposure during therapy.
Sistemska izloženost pri kojoj nije bilo nikakvog učinka u miševa i štakora bila je trostruko odnosno sedmerostruko veća od sistemske izloženosti koja se postiže u ljudi tijekom terapije.
These results indicate that Triumeq can be taken with or without food.
Ovi rezultati pokazuju da se Triumeq može uzimati s hranom ili bez nje.
Patients with chronic hepatitis B or C
Bolesnici s kroničnim hepatitisom B ili C
HLA-B*5701 is the only identified pharmacogenetic marker that is consistently associated with clinical diagnosis of an ABC HSR reaction.
HLA-B*5701 je jedini identificiran farmakogenetski biljeg koji se dosljedno povezuje s kliničkom dijagnozom reakcije preosjetljivosti na abakavir.
In animal reproductive toxicology studies with dolutegravir, no adverse development outcomes, including neural tube defects, were identified (see section 5.3).
U ispitivanjima reproduktivne toksičnosti u životinja nisu primijećeni štetni razvojni ishodi, uključujući defekte neuralne cijevi (vidjeti dio 5.3).
In this condition, parts of the bone tissue die because of reduced blood supply to the bone.
Kod te bolesti dijelovi koštanog tkiva odumiru zbog smanjenog dotoka krvi u kosti.
In vitro, lamivudine was an inhibitor of OCT1 and OCT2; the clinical consequences are not known.
In vitro je lamivudin bio inhibitor prijenosnika OCT1 i OCT2; kliničke posljedice nisu poznate.
During in vitro abacavir selection the M184V mutation occurred first and resulted in about a 2-fold increase in IC50, below the abacavir clinical cut-off of 4.5-fold change.
Tijekom izdvajanja abakavirom in vitro prvo je nastupila mutacija M184V i rezultirala približno dvostrukim povećanjem IC50, što je ispod kliničke granične vrijednosti promjene za abakavir od 4,5.
Additionally, autoinduction of abacavir metabolism or induction of the metabolism of other medicinal products hepatically metabolised has not been observed in humans.
Osim toga, u ljudi nije zabilježena autoindukcija metabolizma abakavira niti indukcija metabolizma drugih lijekova koji se metaboliziraju u jetri.
These mutations have been selected in patients with pre-existing raltegravir resistance and who were then treated with dolutegravir (listed as secondary mutations for dolutegravir).
Te su mutacije izdvojene u bolesnika s već postojećom rezistencijom na raltegravir koji su liječeni dolutegravirom (navodi se kao sekundarna mutacija dolutegravira).
Those reported in at least 10% of patients with a hypersensitivity reaction are in bold text.
Znakovi i simptomi prijavljeni u najmanje 10% bolesnika s reakcijom preosjetljivosti otisnuti su masnim tiskom.
Similar studies were not conducted with either abacavir or lamivudine.
Nisu provedena slična ispitivanja s abakavirom ni lamivudinom.
There are no data available on the safety of abacavir and lamivudine when administered to babies less than three months old.
Nisu dostupni podaci o sigurnosti lamivudina primijenjenog bebama mlađim od tri mjeseca.
G118R lowers the susceptibility to dolutegravir in site directed mutants (fold change 10), but was not detected in patients receiving dolutegravir in the Phase III program.
Mutacija G118R smanjuje osjetljivost izolata s ciljanom mutagenezom (engl. site directed mutants) na dolutegravir (vrijednost promjene 10), ali nije pronađena u bolesnika koji su primali dolutegravir u programu faze III.
Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to CART.
Prijavljeni su slučajevi osteonekroze, osobito u bolesnika s općeprihvaćenim faktorima rizika, uznapredovalom HIV bolešću ili dugotrajnom izloženošću kombiniranoj antiretrovirusnoj terapiji.
The exception was the preputial gland tumour which occurred at a dose of 110 mg/kg in mice.
Izuzetak je bio tumor prepucijske žlijezde, koji se javljao pri dozi od 110 mg/kg u miševa.
It is not known whether abacavir can be removed by peritoneal dialysis or haemodialysis.
Nije poznato može li se abakavir ukloniti peritonejskom dijalizom ili hemodijalizom.
If you forget to take Triumeq
Ako ste zaboravili uzeti Triumeq
Poly(vinyl) alcohol - partially hydrolysed titanium dioxide macrogol talc iron oxide black iron oxide red
Ovojnica tablete poli(vinilni alkohol), djelomično hidroliziran titanijev dioksid makrogol talk željezov oksid, crni željezov oksid, crveni
Outcome Time Point
Razdoblje za ishod
There are limited pharmacokinetic data on subjects with hepatitis B co-infection (see section 4.4).
Farmakokinetički podaci o primjeni u ispitanika s istodobnom infekcijom hepatitisom B su ograničeni (vidjeti dio 4.4).
Purple, biconvex, film-coated oval tablets, approximately 22 x 11 mm, debossed with “572 Trı” on one side.
Filmom obložena tableta (tableta) Ljubičaste, bikonveksne, ovalne filmom obložene tablete, dimenzija približno 22 x 11 mm, s utisnutom oznakom "572 Trı" na jednoj strani.
rhabdomyolysis1
rabdomioliza1
‡ Includes subjects who discontinued due to an adverse event or death at any time point from Day 1 through the Week 48 analysis window if this resulted in no virologic data on treatment during the analysis window.
‡ Uključuje ispitanike koji su prekinuli liječenje zbog nuspojave ili smrti u bilo kojem trenutku od 1. dana do analize nakon 48 tjedana ako zbog toga nisu bili dostupni virološki podaci o liječenju tijekom razdoblja koje je obuhvaćeno analizom.
Primary mutations for raltegravir/elvitegravir (Q148H/R/K, N155H, Y143R/H/C, E92Q, T66I) do not affect the in vitro susceptibility of dolutegravir as single mutations.
Kao pojedinačne mutacije, primarne mutacije raltegravira/elvitegravira (Q148H/R/K, N155H, Y143R/H/C, E92Q i T66I) ne utječu na osjetljivost na dolutegravir in vitro.
HIV-1 resistance to lamivudine involves the development of a M184I or M184V amino acid change close to the active site of the viral RT.
Rezistencija HIV-1 na lamivudin uključuje razvoj promjene na aminokiselini M184I ili M184V u blizini aktivnog mjesta virusne reverzne transkriptaze.
→ Read the information ‘Other possible side effects of combination therapy for HIV' in Section 4 of this leaflet.
Pročitajte informacije u odlomku 'Druge moguće nuspojave na kombiniranu terapiju za HIV ' u dijelu 4. ove Upute.
For abacavir there was a decrease in Cmax with 23% and AUC was unchanged.
Cmax abakavira smanjio se za 23%, dok je AUC ostao neprimijenjen.
→Talk to your doctor for further advice on taking supplements or multivitamins containing calcium, iron or magnesium with Triumeq.
Obratite se svom liječniku za dodatne savjete o uzimanju nadomjestaka ili multivitaminskih pripravaka koji sadrže kalcij, željezo ili magnezij zajedno s lijekom Triumeq.
Therefore, patients should remain under close clinical observation by physicians experienced in the treatment of these associated HIV diseases.
Stoga bolesnici moraju biti pod pomnim kliničkim nadzorom liječnika s iskustvom u liječenju bolesti povezanih s HIV-om.
The median time to viral suppression was shorter with ABC/3TC + DTG (28 vs 84 days, p<0.0001).
Medijan vremena do virusne supresije bio je kraći u skupini koja je primala ABC/3TC + DTG (28 naspram 84 dana, p<0,0001).
Response rates at 96 weeks were 82% for DTG+ABC/3TC and 75% for DRV/r+ABC/3TC.
Stope odgovora na liječenje u 96. tjednu bile su 82% za DTG+ABC/3TC i 75% za DRV/r+ABC/3TC.
• a low red blood cell count (anaemia) or low white blood cell count (neutropenia)
• smanjen broj stanica koje sudjeluju u zgrušavanju krvi (trombocitopenija) • nizak broj crvenih krvnih stanica (anemija) ili nizak broj bijelih krvnih stanica (neutropenija)
Carcinogenicity studies with orally administered abacavir in mice and rats showed an increase in the incidence of malignant and non-malignant tumours.
Ispitivanja kancerogenosti peroralno primijenjenog abakavira u miševa i štakora ukazala su na porast incidencije malignih i nemalignih tumora.
Medicinal products that induce those enzymes or transporters may decrease dolutegravir plasma concentration and reduce the therapeutic effect of dolutegravir (see Table 1).
Lijekovi koji induciraju navedene enzime ili prijenosnike mogu smanjiti koncentraciju dolutegravira u plazmi i tako oslabiti terapijski učinak dolutegravira (vidjeti Tablicu 1).
Abacavir can cause a hypersensitivity reaction (a serious allergic reaction), especially in people who carry a particular type of gene called HLA-B*5701.
Abakavir može uzrokovati reakciju preosjetljivosti (ozbiljna alergijska reakcija), posebno u bolesnika koji imaju gen HLA-B*5701.
The most severe adverse event possibly related to the treatment with dolutegravir and abacavir/lamivudine, seen in individual patients, was a hypersensitivity reaction that included rash and severe liver effects (see section 4.4 and Description of selected adverse reactions in this section).
Najteža nuspojava koja bi mogla biti povezana s liječenjem dolutegravirom i abakavirom/lamivudinom, primijećena u pojedinih bolesnika, bila je reakcija preosjetljivosti, koja je uključivala osip i teške učinke na jetru (vidjeti dio 4.4 i 'Opis odabranih nuspojava' u ovome dijelu).
pure red cell aplasia1
izolirana aplazija crvenih krvnih stanica1
In contrast, starting passage with mutants with mutation Q148H (fold change 1), a variety of raltegravir associated secondary mutations accumulated with a consequent increase of fold change to values >10.
Nasuprot tome, ako je pasaža započela s mutantima koji su imali mutaciju Q148H (vrijednost promjene 1), akumulirao se niz različitih sekundarnih mutacija povezanih s primjenom raltegravira, što je za posljedicu imalo porast vrijednosti promjene na >10.
EFV/TDF/FTC once daily N=419
EFV/TDF/FTC jedanput na dan N=419
Such infections may have been “silent” and not detected by the weak immune system before treatment was started.
Takve su infekcije prije liječenja možda bile 'u mirovanju' pa ih oslabljen imunosni sustav nije mogao prepoznati.
The combination of abacavir/lamivudine has demonstrated decreased susceptibility to viruses with the substitutions K65R with or without the M184V/I substitution, and to viruses with L74V plus the M184V/I substitution.
Kombinacija abakavir/lamivudin pokazala je smanjenu osjetljivost na viruse sa supstitucijama K65R, koji mogu ili ne moraju imati supstituciju M184V/I, te na viruse sa supstitucijom L74V i M184V/I.
The pharmacokinetics of abacavir in patients with end-stage renal disease is similar to patients with normal renal function.
Farmakokinetika abakavira u bolesnika u terminalnoj fazi bubrežne bolesti slična je onoj u bolesnika s normalnom bubrežnom funkcijom.
GlaxoSmithKline Pharmaceuticals S.A., UL.Grunwaldzka 189, 60-322 Poznan, Poland
GlaxoSmithKline Pharmaceuticals S.A., UL.Grunwaldzka 189, 60-322 Poznan, Poljska
If you have discontinued Triumeq due to this reaction, YOU MUST NEVER TAKE Triumeq, or any medicine containing abacavir again as within hours you may experience a life-threatening lowering of your blood pressure or death.
Ako ste prestali uzimati lijek Triumeq zbog te reakcije, VIŠE NIKADA NE SMIJETE UZIMATI Triumeq niti druge lijekove koji sadrže abakavir jer unutar svega nekoliko sati može doći do po život opasnog pada krvnog tlaka ili smrti.
Immune system disorders: Common hypersensitivity (see section 4.4)
Poremećaji imunološkog sustava: često preosjetljivost (vidjeti dio 4.4)
Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg (see sections 4.4 and 5.1).
Triumeq je indiciran za liječenje odraslih osoba i adolescenata starijih od 12 godina i tjelesne težine najmanje 40 kg, zaraženih virusom humane imunodeficijencije (HIV) (vidjeti dijelove 4.4 i 5.1).
For general Triumeq information enquiries, contact:
Za općenite informacije o lijeku Triumeq kontaktirajte:
IMPORTANT - PATIENT ALERT CARD Triumeq (dolutegravir / abacavir / lamivudine) tablets Carry this card with you at all times
Triumeq (dolutegravir / abakavir / lamivudin) tablete Ovu karticu uvijek nosite sa sobom
Hypersensitivity reaction observed for each of these medicinal products (described below) share some common features such as fever and/or rash with other symptoms indicating multi-organ involvement.
Reakcije preosjetljivosti primijećene kod primjene svakog od tih lijekova zasebno (opisane u nastavku) dijele neke značajke, poput vrućice i/ili osipa praćenih drugim simptomima koji upućuju na zahvaćenost većeg broja organa.
The effect of the Q148-based mutations (H/R/K) was also consistent with in vitro passage experiments with site directed mutants.
Učinak mutacija Q148 (H/R/K) bio je u skladu i s pokusima pasaže in vitro na izolatima s ciljanom mutagenezom.
The effect of food on plasma exposures of abacavir and lamivudine following administration of Triumeq with a high fat meal were very similar to prior food effects observed with ABC/3TC FDC.
Učinak hrane na plazmatsku izloženost abakaviru i lamivudinu nakon primjene lijeka Triumeq uz obrok s visokim udjelom masnoća bio je vrlo sličan učincima hrane prethodno primijećenima nakon primjene fiksne kombinacije ABC/3TC.
Based on in vivo and/or in vitro data, dolutegravir is not expected to affect the pharmacokinetics of medicinal products that are substrates of any major enzyme or transporter such as CYP3A4, CYP2C9 and P-gp (for more information see section 5.2).
Na temelju in vivo i/ili in vitro podataka, ne očekuje se da će dolutegravir utjecati na farmakokinetiku lijekova koji su supstrati glavnih enzima ili prijenosnika kao što su CYP3A4, CYP2C9 i P-gp (za više informacija vidjeti dio
No clinically important pharmacokinetic differences between subjects with severe renal impairment (CLcr <30 mL/min) and matching healthy subjects were observed.
Nisu primijećene klinički značajne farmakokinetičke razlike između ispitanika s teškim oštećenjem bubrežne funkcije (CLcr <30 ml/min) i odgovarajućih zdravih ispitanika.
Based on limited available data with the dolutegravir single entity used in combination with other antiretroviral agents to treat adolescents (12 to 17 years), there were no additional types of adverse reactions beyond those observed in the adult population.
Ograničeni dostupni podaci o dolutegraviru kao pojedinačnoj djelatnoj tvari primijenjenoj u kombinaciji s drugim antiretroviroticima za liječenje adolescenata (u dobi od 12 do 17 godina) nisu ukazali na dodatne vrste nuspojava u odnosu na one primijećene u odrasloj populaciji.
The most frequently reported adverse reactions considered possibly or probably related to dolutegravir and abacavir/lamivudine were nausea (12%), insomnia (7%), dizziness (6%) and headache (6%).
Sažetak sigurnosnog profila Najčešće prijavljene nuspojave čija se povezanost s primjenom dolutegravira i abakavira/lamivudina smatra mogućom ili vjerojatnom bile su mučnina (12%), nesanica (7%) omaglica (6%) i glavobolja
At baseline, median patient age was 35 years, 16% were female, 32% non-white, 7% had hepatitis C coinfection and 4% were CDC Class C, these characteristics were similar between treatment groups.
Na početku ispitivanja medijan dobi bolesnika iznosio je 35 godina, 16% bolesnika bile su žene, 32% bolesnika nisu bili bijelci, 7% bolesnika imalo je istodobnu infekciju hepatitisom C, a 4% bolesnika imalo je HIV infekciju kategorije C prema CDC
The clinical relevance of this is unknown.
Klinički značaj toga nije poznat.
After 24 weeks all remaining subjects switched to ABC/DTG/3TC FDC (Late Switch).
Nakon 24 tjedna, svi preostali ispitanici prešli su na fiksnu kombinaciju ABC/DTG/3TC (kasni prelazak).
Dolutegravir had no Pharmacodynamic effect on Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH) and progesterone.
Dolutegravir nije utjecao na farmakodinamiku luteinizirajućeg hormona (LH), folikulostimulirajućeg hormona (FSH) niti progesterona.
Arthralgia1, muscle disorders1(including myalgia1)
artralgija1, mišićni poremećaji1 (uključujući mijalgiju1)
Total blood and plasma drug-related radioactivity concentration ratios averaged between 0.441 to 0.535, indicating minimal association of radioactivity with blood cellular components.
0,441 i 0,535, što ukazuje na minimalnu povezanost radioaktivnosti s krvnim stanicama.
If you are taking methadone, you will be checked for any withdrawal symptoms.
Ako uzimate metadon, liječnik će Vas nadzirati zbog moguće pojave simptoma ustezanja.
TRIUMEQ TABLETS PATIENT ALERT CARD SIDE 1
TRIUMEQ TABLETE - KARTICA S UPOZORENJIMA ZA BOLESNIKA